Reindeer

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
Thursday, April 4, 2024

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

RegCell Appoints Leading T-Cell Therapy Expert Steven B. Kanner, Ph.D., to Board of Directors

Retrieved on: 
Wednesday, April 3, 2024

"We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.

Key Points: 
  • "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
  • "Dr. Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform.
  • Backed by leading institutional and corporate investors hailing from Japan, RegCell emerges as the next-generation global life science enterprise at the forefront of regulatory T-cell therapies.
  • Central to RegCell's innovation is its 'Precision Epigenetic Reprogramming' platform, which entails the epigenetic reprogramming of CD4+ T-cells into regulatory T-cells.

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 25, 2024

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

Key Points: 
  • SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
  • "Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida.
  • Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.
  • Prior to joining Caribou, he served as Chief Medical Officer at Chimeric Therapeutics, where he helped build the company's pipeline by licensing programs from leading universities and progressing existing programs through the clinical development process.

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Retrieved on: 
Tuesday, February 20, 2024

This approach is proprietary to Precision and results in T cells suitable for allogeneic use.

Key Points: 
  • This approach is proprietary to Precision and results in T cells suitable for allogeneic use.
  • Under the terms of the agreement, Precision will receive an upfront payment and, upon commercialization by Caribou, royalties on net sales of licensed products.
  • In addition, for each occurrence of certain strategic transactions involving Caribou, Precision is eligible to receive a specific tiered milestone payment.
  • This patent family is potentially also available for non-exclusive license to other high-quality partners in the cell therapy space.

Chronic wasting disease has been detected in British Columbia deer, and we need to act now

Retrieved on: 
Friday, February 16, 2024

Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.

Key Points: 
  • Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.
  • On Jan. 31, 2024, chronic wasting disease (CWD) was detected for the first time in British Columbia in two deer.

Disease-causing proteins

  • The protein is similar to other normal proteins in the body, except it’s abnormally shaped.
  • The abnormal folding of these disease-causing prion proteins — which are found most abundantly in the brain — leads to brain damage that makes the brain appear like a sponge.
  • Other TSEs include Creutzfeldt-Jakob disease in people, bovine-spongiform encephalopathy (“mad cow disease”) in cows, and scrapie in sheep and goats.
  • This means that early detection and management is critical for reducing the impact of this disease.

British Columbia’s preparations

  • has established a surveillance program to detect CWD as soon as possible.
  • Our research suggests that a robust approach to such a difficult disease will require rapid, collective and collaborative action across sectors.
  • This approach must involve wildlife managers, hunters, local communities, First Nations and researchers to integrate a number of approaches.

Surveillance and management

  • Many CWD management programs rely on removing infected animals from the landscape.
  • While it is mandatory to submit the heads from hunted cervids in select management units in B.C., in most regions, submission is voluntary.
  • Hunters can participate in CWD management and surveillance by removing the head of the animal and submitting it to a local testing station or freezer for CWD testing.
  • The public can also participate in CWD surveillance and management by reporting signs of sick animals and vehicle collisions with cervids.
  • This is why testing cervids that have been killed by vehicles is also a critical component of CWD surveillance and management.

Curbing the spread

  • CWD can spread between animals through contact with bodily fluids.
  • Legal restrictions on carcass transport and the use of urine-based scents in hunting can also reduce the unintentional spread of CWD.
  • Research has shown that community-focused communication and engagement are essential for the success of CWD management efforts.
  • In the days ahead, fostering open dialogue and collaboration will be paramount towards an effective and sustainable effort against CWD.


Kaylee Byers is the Regional Deputy Director of the British Columbia Node of the Canadian Wildlife Health Cooperative and collaborates with the Wildlife Health Program, which leads Chronic Wasting Disease surveillance in British Columbia. Sarah Robinson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Caribou Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 15, 2024

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

Key Points: 
  • BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:
    For more information and links to available webcasts, visit the Events page on Caribou’s website.
  • Webcasts will be available on the Caribou website for 30 days after the events.

Stone Age ‘megastructure’ under Baltic Sea sheds light on strategy used by Palaeolithic hunters over 10,000 years ago

Retrieved on: 
Thursday, February 15, 2024

Archaeologists have identified what may be Europe’s oldest human-made megastructure, submerged 21 metres below the Baltic Sea in the Bay of Mecklenburg, Germany.

Key Points: 
  • Archaeologists have identified what may be Europe’s oldest human-made megastructure, submerged 21 metres below the Baltic Sea in the Bay of Mecklenburg, Germany.
  • This structure – which has been named the Blinkerwall – is a continuous low wall made from over 1,500 granite stones that runs for almost a kilometre.
  • The evidence suggests it was constructed by Palaeolithic people between 11,700 and 9,900 years ago, probably as an aid for hunting reindeer.

A different landscape

  • At the time of its construction, the landscapes and seascapes of northwest Europe were very different from today.
  • Herds of reindeer, European bison and wild horse migrated across its sparsely forested landscape.
  • The identification of the Blinkerwall now demonstrates that Palaeolithic hunters were managing their landscape to aid their hunting activities more deliberately than was previously thought.
  • Construction of walls and other features in the landscape is familiar to us, particularly in the context of land enclosure for farming.

Supporting evidence

  • One archaeological site from Germany that supports this interpretation is Stellmoor, located just north of Hamburg and which dates to the latest time that the Blinkerwall could have been constructed.
  • The hunting evidence at Stellmoor shows the reindeer were shot by arrows as they were driven down the valley into the lake.
  • While there is no archaeological evidence at Stellmoor to suggest people had deliberately created or changed the landscape to enhance their hunting success, it shows how the topography of the landscape was used to the hunters’ advantage.
  • The Blinkerwall construction provides evidence that Palaeolithic people took this level of planning and coordination a step further.
  • The Bay of Mecklenburg has the potential to reveal further archaeological evidence of equal significance.


Stephanie Piper does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

ATLAS OCEAN VOYAGES HIGHLIGHTS TWO YACHTS FOR THE FIRST TIME IN THE ARCTIC FOR SUMMER 2024

Retrieved on: 
Thursday, January 25, 2024

FORT LAUDERDALE, Fla., Jan. 25, 2024 /PRNewswire/ -- Atlas Ocean Voyages, the leader in yacht expedition cruising, is excited to highlight the 2024 Arctic Season featuring two yachts in the region for the first time. World Traveller and World Navigator will sail 11 expeditions ranging from 7 to 12 nights, exploring the captivating Arctic region with departures from Tromso, Oslo, Longyearbyen, Reykjavik, and Kangerlussuaq. Enjoy the convenience of inclusive charter jet air service from either New York John F. Kennedy International Airport or Oslo Gardermoen Airport on select expeditions.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 25, 2024 /PRNewswire/ -- Atlas Ocean Voyages , the leader in yacht expedition cruising, is excited to highlight the 2024 Arctic Season featuring two yachts in the region for the first time.
  • Atlas Ocean Voyages is excited to highlight the 2024 Arctic Season featuring two yachts.
  • Every Polar Expedition by Atlas 2024 Arctic voyage includes a free Cultural Immersion experience, offering guests unique insights into local communities.
  • Atlas Ocean Voyages invites adventurers to embark on these unprecedented Arctic expeditions, where each journey promises awe-inspiring landscapes, cultural encounters, and unparalleled experiences.